MARATTO

article · BMC Chemistry

Green TLC-densitometric method for determination of cytarabine and granisetron in spiked human plasma: optimization and whiteness assessment

2026Open accessBeni Suef University

Abstract

Cytarabine (CYT) is a cornerstone in the treatment of acute myeloid leukemia (AML) and is often co-administered with granisetron (GRS) to manage chemotherapy-induced nausea and vomiting (CINV). A precise and sensitive thin-layer chromatographic (TLC) method was developed and validated for the simultaneous determination of CYT and GRS in spiked human plasma samples. Chromatographic separation was achieved by using a developing system consisting of ethyl acetate, ethanol, and ammonia (3:6.8:0.2, by volume), and detection was performed at 240 nm. The method exhibited linearity over the concentration ranges of 0.5-3.0 µg/band for the pure samples and 0.5-3.3 µg/band in spiked plasma for the analytes. The proposed method was validated in accordance with the guidelines of the U.S. Food and Drug Administration (FDA). Its environmental sustainability was evaluated using the Modified Green Analytical Procedure Index, Analytical Greenness Calculator, and Multicolor Assessment Index, demonstrating strong performance with minor areas for improvement. Notably, this study presents the first green TLC method for the simultaneous determination of CYT and GRS in spiked human plasma, offering a valuable tool for therapeutic drug monitoring during chemotherapy.

Research topics

  • Nausea and vomiting management
  • Chemotherapy-induced organ toxicity mitigation
  • Analytical Methods in Pharmaceuticals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s13065-026-01821-1

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.